Association between B7-H1 expression and bladder cancer: a meta-analysis

Wang, Y.U.; Liu, A.N.G.; Zhao, Shan

doi:10.4238/2015.february.13.6

Cited by 2 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, two meta-analyses focused on PD-L1 and UC survival were reported. Wu et al [ 34 ] indicated that PD-L1 status was related with worse 3-year overall survival in UC, and Wang et al [ 35 ] revealed that PD-L1 status could predict the clinical stage of UC. Our pooled results with HR value and 95% CI raised a doubt and showed different results with them.…”

Section: Discussionmentioning

confidence: 99%

Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis

Liu

Yang

et al. 2020

Disease Markers

View full text Add to dashboard Cite

Recently, checkpoint inhibition of the PD-1/PD-L1 axis has been shown to be therapeutically relevant in urothelial carcinoma (UC). To evaluate the predictive and prognostic value of PD-L1 on response and survival in UC patients after cystectomy, chemotherapy, or anti-PD-1/PD-L1 therapy, a systematic review of PubMed, Embase, Web of Science, and the Cochrane Library was performed. A total of 2154 patients from 14 published studies were included. In all UC patients after cystectomy, tumour cell (TC) PD-L1 expression was not associated with the OS or PFS. For the subset of patients with organ-confined disease, TC PD-L1 expression significantly predicted OS after cystectomy (P=0.0004). There was no significant evidence of an association between TC PD-L1 status and ORR or OS for UC patients treated with platinum-based chemotherapy. For UC patients treated with anti-PD-1/PD-L1 therapy, TC PD-L1 expression≥5% could predict the response (P=0.005), but not for the 1% cut-off (P≥0.05). As for PD-L1 expression in tumour-inflating immune cells (TIICs), both subsets with IC2/3 vs. IC0/1 and IC1/2/3 vs. IC0 were associated with ORR to anti-PD-1/PD-L1 therapy. In the TIIC subset, IC2/3 vs. IC0/1 of PD-L1 was associated with higher CR (P=0.002), PR (P=0.04), and PD (P=0.007). Further, higher TIIC PD-L1 status benefited from longer PFS (P<0.001), but was not associated with OS in UC patients with anti-PD-1/PD-L1 therapy. Our study suggested that TIIC PD-L1 expression with 5% cut-off was valuable as a predictive and prognostic biomarker for ORR and PFS in UC patients with anti-PD-1/PD-L1 therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis

Liu

Yang

et al. 2020

Disease Markers

View full text Add to dashboard Cite

show abstract

“… 15 Interestingly, patients with superficial BCa showed lower PD-L1 expression than those with invasive BCa. 16 Moreover, blockade of the PD-1/PD-L1 axis was shown to induce a potent antitumor immune response in preclinical mouse models as well as in the clinic. 17,18 Based on the efficacy of Anti-PD-L1 directed therapy, the FDA granted a Breakthrough Therapy Designation for the use of Anti-PD-L1 (MPDL3280A) in metastatic BCa in 2014.…”

Section: Introductionmentioning

confidence: 99%

Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer

et al. 2016

View full text Add to dashboard Cite

The infiltration of myeloid cells helps tumors to overcome immune surveillance and imparts resistance to cancer immunotherapy. Thus, strategies to modulate the effects of these immune cells may offer a potential therapeutic benefit. We report here that tasquinimod, a novel immunotherapy which targets S100A9 signaling, reduces the immunosuppressive properties of myeloid cells in preclinical models of bladder cancer (BCa). As single anticancer agent, tasquinimod treatment was effective in preventing early stage tumor growth, but did not achieve a clear antitumor effect in advanced tumors. Investigations of this response revealed that tasquinimod induces an increase in the expression of a negative regulator of T cell activation, Programmed-death-ligand 1 (PD-L1). This markedly weakens its antitumor immunity, yet provokes an “inflamed” milieu rendering tumors more prone to T cell-mediated immune attack by PD-L1 blockade. Interestingly, the combination of tasquinimod with an Anti-PD-L1 antibody enhanced the antitumor immune response in bladder tumors. This combination synergistically modulated tumor-infiltrating myeloid cells, thereby strongly affecting proliferation and activation of effector T cells. Together, our data provide insight into the rational combination of therapies that activate both innate and adaptive immune system, such as the association of S100A9-targeting agents with immune checkpoints inhibitors, to improve the response to cancer immunotherapeutic agents in BCa.

show abstract

Association between B7-H1 expression and bladder cancer: a meta-analysis

Cited by 2 publications

References 32 publications

Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis

Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis

Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer

Contact Info

Product

Resources

About